



Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome

Expert Faculty for Content Committee

<p>Rosario Pivonello, MD, PhD Associate Professor of Endocrinology Department of Clinical Medicine and Surgery Federico II University Naples, Italy</p>	<p>Irina Bancos, MD Professor of Medicine Division of Endocrinology, Metabolism and Nutrition Joint Appointment Department of Laboratory Medicine and Pathology Rochester, Minnesota</p>
--	---

Learning Objectives

After participating in the activity, learners should be better able to:

1. Review the guideline- and evidence-based screening and diagnostic strategies for Cushing Syndrome.
2. Evaluate the need for referral to a specialist for Cushing Syndrome treatment.
3. Summarize current treatment options for medical management of Cushing Syndrome in patients who are not surgical candidates, are awaiting a surgical consult, or prefer medical therapy over surgery.
4. Collaborate as a team to design individualized, evidence-driven screening and medical management plans for patients with Cushing Syndrome, focusing on the role of the interprofessional and interdisciplinary team.
5. Apply the principles of shared decision-making to real-world patient cases, focusing on screening, initial treatment and monitoring/follow-up of patients with Cushing Syndrome.

Accreditation and Credit Designation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In order to improve patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstone Medical Education. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours.

Pharmacists

This activity provides 1.0 ACPE contact hours (0.1 CEUs) of continuing education credit.

Target Audience

This activity has been designed to meet the educational needs of the Cushing Syndrome (CS)/hypercortisolism care team, including endocrinologists, primary care physicians, cardiologists, nephrologists, and the interprofessional care team of advanced practice providers (nurse practitioners and physician assistants), nurses and pharmacists.

Support

This activity is supported by an independent educational grant from Corcept Therapeutics.

Disclosures

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Rosario Pivonello, MD, PhD (Planner/Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Inc.; Grant/Research Support: Corcept Therapeutics, Neurocrine Biosciences, Recordati Rare Diseases, Inc., Esteve Pharmaceuticals, Spruce Bioscience, and Xeris Pharmaceuticals

Irina Bancos, MD (Planner/Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Corcept Therapeutics, Crinetics Pharmaceuticals, Camurus, Adrenas Therapeutics, Neurocrine Biosciences, Diurnal, Spruce Biosciences, Adaptyx, Lifordi Immunotherapeutics, Xeris Pharmaceuticals, Novo Nordisk, AstraZeneca, Recordati Rare Diseases, Inc.; Grant/Research Support: Esteve Pharmaceuticals and Recordati Rare Diseases, Inc.

Amir Hamrahian, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Crinetics Pharmaceuticals, Recordati Rare Diseases, Inc., Corcept Therapeutics, Cristcot; Grant/Research Support: Recordati Rare Diseases, Inc., Corcept Therapeutics, Lundbeck, AstraZeneca, Spruce Biosciences, Crinetics Pharmaceuticals; Data Monitoring Committee: Paradigm Biopharma

Honey East, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Amgen, Corcept Therapeutics, Regeneron; Grant/Research Support: Corcept Therapeutics, Novartis, Thermo Fisher Scientific; Speaker's Bureau: Amgen, Corcept Therapeutics, Lilly

Off-Label Usage: This presentation includes discussion of off-label/investigational uses.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Cornerstone Medical Education. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Copyright © 2026